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Summary In cancer-treatment, potentially therapeutic
drugs trigger their effects through apoptotic mechanisms.
Generally, cell response is manifested by Bcl-2 family
protein regulation, the impairment of mitochondrial func-
tions, and ROS production. Notwithstanding, several drugs
operate through proteasome inhibition, which, by inducing
the accumulation and aggregation of misfolded or unfolded
proteins, can lead to endoplasmic reticulum (ER) stress.
Accordingly, it was shown that Amblyomin-X, a Kunitz-
type inhibitor identified in the transcriptome of the
Amblyomma cajennense tick by ESTs sequence analysis of
a cDNA library, obtained in recombinant protein form,
induces apoptosis in murine renal adenocarcinoma
(RENCA) cells by: inducing imbalance between pro- and
anti-apoptotic Bcl-2 family proteins, dysfunction/mitochon-
drial damage, production of reactive oxygen species (ROS),
caspase cascade activation, and proteasome inhibition, all
ER-stress inductive. Moreover, there was no manifest action
on normal mouse-fibroblast cells (NHI3T3), suggesting an
Amblyomin-X tumor-cell selectivity. Taken together, these
evidences indicate that Amblyomin-X could be a promising
candidate for cancer therapy.
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Abbreviations
ROS reactive oxygen species
RNS reactive nitrogen species
NO nitric oxide
ER endoplasmatic reticulum
eIF2α alpha subunit of translation initiation factor
GRP78 78kDa glucose-regulated protein
GADD153 nuclear transcription factors of growth
arrest and DNA damage
RENCA murine renal adenocarcinoma
SEM scanning electron microscopy
UPR unfolded protein response
[Ca2+]i intracellular calcium concentration
Introduction
Apoptosis induction has been the subject of many studies,
not only of therapeutic potential, but also for a better under-
standing of the cell mechanisms involved in various forms
of biological response, such as aging [1–3]. The process
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itself comprises a highly conserved mechanism, which can
be induced by a variety of physiological or pathological
conditions, in which caspases and mitochondria play a cru-
cial role [4]. Except for death-domain receptors, the molec-
ular mechanisms by which the many different pro-apoptotic
stimuli, such as irradiation, chemotherapeutics or growth
factor depletion, signal and initiate mitochondrial changes,
are currently not well understood. There is agreement that
cytochrome c action has two important consequences: (a)
caspase cascade activation by the interaction of cytochrome
c with Apaf-1 and procaspase-9; and (b) inhibition of the
mitochondrial electron transfer chain, thereby resulting in
the reduction of oxidative phosphorylation, inducement of
reactive oxygen species (ROS) production, and finally,
impairment of cellular ATP production during secondary
necrosis [5].
Although mitochondria are the major source of ROS,
these can also be derived from several intracellular sources,
including NAD(P)H oxidase, xanthine oxidase, uncoupled
nitric oxide synthase and ER stress [6–8]. Apoptosis is also
regulated by various ROS and nitrogen species (RNS)
[8–10]. ROS, such as hydrogen peroxide (H2O2), superox-
ide radicals (O2
•-) and hydroxyl radicals (•OH), by-products
of normal oxygen metabolism, participate in normal cell
functions, and act as intracellular signaling molecules in a
series of biological processes [9–11]. Nevertheless, imbalance
in ROS production may have a cytotoxic effect. Furthermore,
subtle changes in the RNS production rate, as nitric oxide
(NO), may critically impact cell homeostasis, thereby
initiating a series of cellular signaling processes, including
apoptosis [9, 12].
Bcl-2 and p53 proteins are among those involved in
mitochondrial dysfunction and damage, as well as ROS
production [13, 14]. The Bcl-2 proteins are located within
the outer mitochondrial membrane, the nuclear envelope
and the endoplasmic reticulum (ER) of cells. Whereas
anti-apoptotic proteins stabilize the mitochondrial mem-
brane, pro-apoptotic proteins induce the release of cyto-
chrome c, thereby activating effector caspases, such as
caspase-3 [15–17]. p53 proteins, known as the "guardians
of the genome", play an important role in maintaining DNA
integrity and apoptosis induction, by selectively removing
damaged cells and protecting the organism against cancer
development [18–20]. It is well known that p53 are involved
in the regulation of the transcriptional levels of pro- and
anti-apoptotic genes, death receptors, and those other factors
involved in the different steps of the apoptotic pathway [14].
For example, this protein can directly activate Bax [21], or
directly bind to Bcl-XL [22] and Bcl-2 proteins, in order to
induce mitochondrial permeabilization, and thus release
cytochrome c.
Certain chemotherapeutic drugs have been specifically
designed to induce apoptosis through mitochondrial
dysfunction and damage, and ROS production, thus activat-
ing cytotoxic action. Nonetheless, some of these, most no-
tably proteasome inhibitors, induce cell death through the
ER-stress mediated apoptotic pathway [23–25]. ER organ-
elle is involved in the synthesis, structural modification and
transport of proteins and lipids [26]. When newly synthe-
sized proteins in ER do not present a correct folding, they
are retro-translocated to the cytosol, where they are imme-
diately directed to proteassomal degradation [27, 28]. This
mechanism plays an important role in reducing the amount
of misfolded or unfolded proteins in ER. The blockage of
proteasome proteolytic activity by pharmacological inhibi-
tors, such as bortezomib/PS-341, severely compromises the
removal of proteins with impaired conformational structure,
thereby leading to their subsequent accumulation inside the
ER lumen, with the consequential overloading [29, 30].
When these acute or chronic structural and functional dis-
turbances reach the point of compromising ER integrity,
there is a specific stress response, which, by various mech-
anisms, activates anti-apoptotic, apoptotic cell, or block cell
cycle progression [31]. Amongst others, ER stress involves
(a) specific transcriptional and translational responses, such
as, phosphorylation of the alpha subunit of the translation
initiation factor eIF (eIF2α), (b) the activation of chaperone
78 kDa glucose-regulated protein (GRP78), as well as nu-
clear transcription factors of growth arrest and DNA damage
(GADD153), (c) ER-specific caspase-12, and (d) calcium
imbalance [32, 33].
Within this context, Amblyomin-X was recently
shown to be a proteasomal inhibitor, selectively pro-
apoptotic activity in tumor human cells (SK-Mel-28 and
Mia-Paca-2) [34]. This molecule, obtained in recombi-
nant protein form, is a Kunitz-type inhibitor (GenBank
accession AAT68575) identified in the transcriptome of
the Amblyomma cajennense tick by ESTs sequence anal-
ysis of a cDNA library [35]. Simultaneous studies of
Murine Renal Adenocarcinoma cells (RENCA) have
shown that Amblyomin-X is also capable of inducing
apoptosis in this lineage [36]. In this report, it was
demonstrated that the pro-apoptotic mechanisms used
by Amblyomin-X to trigger effects in RENCA cells,
include pro- and anti-apoptotic Bcl family protein acti-
vation, dysfunction/mitochondrial damage, ROS produc-
tion, caspase-cascade activation and proteasome inhibition, all
capable of inducing ER stress.
Material and methods
Amblyomin-X expression
The recombinant protein was prepared as described
elsewhere [35].
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Cell Culture
RENCA cells were cultured in RPMI, supplemented with
10 % fetal bovine serum, 0.1 mM of nonessential amino
acids, 1 mM of sodium pyruvate, 2 mM of L-glutamine,
100 mg/mL of streptomycin sulfate and 100 U/mL of pen-
icillin G. The strain was kindly provided by Dr. Maria
Helena Bellini Marumo (Institute of Energy and Nuclear
Research—IPEN—in São Paulo, Brazil), wich in turn
received from Dr. Isaiah J. Fidler (The University of Texas
M. D. Anderson Cancer Center, Houston, TX)[36–38]. It is
an epithelial renal cell carcinoma of conventional type, clear
cell (ccRCC) from spontaneous tumor growth in renal cor-
tical tissue of mice of the Balb/c tha was isolated in 1969
and established as a cell line in 1973[39]. The NIH3T3
mouse fibroblast cells [ATCC No. CRL-1658] were cultured
in DMEM , supplemented with 10 % fetal bovine serum,
100 mg/mL of streptomycin sulfate and 100 U/mL of
penicillin G. RENCA and NIH3T3 cells were kept at 37 °C
in a 5 % CO2 atmosphere. The medium was changed after
12 h, and then every 3 days.
Cell micromorphological analysis by scanning electron
microscopy (SEM)
In order to facilitate protein penetration and precipitation,
and ensure optimal preservation of their ultrastructures,
RENCA and NIH3T3 cells were fixed with 3 % glutaralde-
hyde for 24 h. Subsequently, the samples were washed 5
times in a cacodylate buffer, prior to post-fixing in 4 %
buffered OsO4 for 1 h, followed by further buffer-washing.
Prior to treatment with or without 0.1 µM of Amblyomin-X,
the cell suspension was centrifuged at 1500 rpm for 5 min,
re-suspended in RPMI-1640 supplemented with 10 % FBS,
and cultured in 2 cm2 petri dishes at a density of 106 cells/
mL. After 24-hours of treatment, the cells were referenced
for normal NIH/3 T3 fibroblasts, before transferring to
permeable critical-point apparatus for double dehydrating
in alcohol baths at 30, 50, 70, 80, 95 and 100 % concentra-
tion. Several changes were required to so ensure complete
removal of all the water content. Drying of the samples was
performed at critical point apparatus using carbon dioxide
and the plates received the metallic coating with gold
by sputtering. Finished processing the material was
observed and analyzed in a Philips XL30 scanning-electron
microscope.
Determination of the proteins involved in apoptosis
and mitochondrial events by flow cytometry
Flow cytometry was applied to evaluating pro- and anti-
apoptotic protein expression, cytochrome c measurement,
the analysis of mitochondrial membrane potencial, and
caspase activation. Accordingly, RENCA and NIH3T3
5x105 cells were placed on 6-well-plates with a culture
medium supplemented with fetal bovine serum. After cell
adhesion, Amblyomin-X was added to the cell culture for
24 h, in a final concentration of 0.1 μM.
So as to assess Bcl-2 family expression and caspase 3
activation, cell concentration was first adjusted to
5x105cells/mL, whereupon aliquots of 100 μL of cell sus-
pension were permeabilized with a solution of Triton X-100
0.1 % in FACs buffer Flow (BD), and then incubated for 1 h
at 4 °C with 1 μg of either of three specific antibodies, anti-
Bad, anti-Bax or anti-Bcl-2, conjugated with FITC (Santa
Cruz, USA), and 1 μg of specific antibody anti-Caspase 3
phosphorylated phycoerythrin conjugated-PE (Santa Cruz,
USA), in either the presence or absence of its specific Ac-
Asp-Glu-Val-sp-OH inhibitor (BioAgency Biotechnology).
Subsequently, the cells were centrifuged for 10 min at
1500 rpm and washed with cold PBS. The supernatant was
discarded, and the cell-button again suspended in PBS
containing 1 % of paraformaldehyde. The reading and anal-
ysis of expression in arbitrary units of fluorescence of cell
surface receptors were performed with a flow cytometer
(Becton Dickinson, San Jose, CA, USA).
Cells present in the supernatant, as well as those trypsi-
nized adherent, were transferred to cytometer tubes, and
fixed with 4 % paraformaldehyde, in order to evaluate
cytochrome c release and p53 expression. Cells were per-
meabilized with 0.5 % saponin in PBS for 30 min at room
temperature. In sequence, cells were washed with a buffer
Fac's flow containing 0.1 % saponin in PBS solution
(BSA/saponin), and then incubated with monoclonal an-
tibody anti-cytochrome c (Santa Cruz USA) and anti-p53
(Santa Cruz, USA), at a concentration of 1 μg of anti-
body per 106 cells, during 18 h at 4 °C. They were then
washed with BSA/saponin and incubated with a second-
ary antibody conjugated with phycoerythrin—PE (1 μg).
After incubation for 2 h at 37 °C, they were again
washed with PBS and fixed in 1 % paraformaldehyde.
Accompaniment throughout the whole process was done
by isotype control.
Electric potential was assessed by mitochondrial efflux-
ing of fluorescent probe Rhodamine-123, with a functional
MDR phenotype as control. Briefly, 300 μL of cell suspen-
sion were incubated with or without Rhodamine-123 probe
(200 ng/mL) in a humidified 5 % CO2 incubator for 45 min
at 37 °C. After centrifugation for 30 min at 1500 rpm, the
cells were washed in cold PBS, and mitochondrial potential
measured with a flow cytometer. Histograms of fluorescence
intensity were obtained from the gates of cells tested. The
results were analyzed as mean fluorescence intensity (MFI),
by MFI ratio of the sample under study and its negative
control. In this study, 1x104 cells per sample were analyzed
with Cell Quest (BD) version 3.1, and FSC (size) and SSC
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(granularity/complexity) FL1/FL2 as parameters, to evaluate
fluorescence intensity of the binding reaction antigen/anti-
body conjugated to PE and/or FITC. All acquisitions were
done in three independent experiments.
Proteasome activity
Proteassome activity was determined according to Chudzinski
et al. [34]. RENCA and NIH3T3 cells were treated with
0.1 μM of Amblyomin-X for two periods of 4 and 16 h. The
cells were then washed twice with PBS and mechanically
lysed. After quantification of total proteins in the cell ex-
tract, aliquots of 15–30 μg were separated for measuring
proteasome activity. Fluorogenic peptides (AMC, 7-amide-
4-methylcoumarin; Calbiochem, San Diego, CA, USA)
were used to determine proteasomal activity, Suc-LLVY-
AMC, the standard peptide for assessing chymotrypsin-
like activity and z-ARR-AMC, was used to determine
trypsin-like activity. The cell extracts obtained were incu-
bated at 37 °C with 125–500 mM of fluoropeptides. Fluo-
rescence emission at 440 nm (excitation at 365 nm) was
recorded for 1 h. The calculation of final results, expressed
as the percentage of hydrolysis measured in total extracts
from untreated control cells, was based on the difference
between total cell-extract hydrolytic activity, and the activity
determined in samples previously incubated with standard
proteasome inhibitors (lactacystin or NLVS). All the experi-
ments were carried out in triplicate.
Calcium measurement by confocal microscopy
Before measuring changes in [Ca2+]i levels in RENCA cells
by calcium imaging with a LSM 510 Meta confocal micro-
scope (Zeiss, Jena, Germany), 2.5x105 cells were seeded
and attached to cover slides in p60-mm culture dishes
(Nalge Nunc International, Rochester, NY), prior to pre-
treatment with 0.5 μM of Amblyomin-X at intervals of 5
and 24 h. After loading for 30 min at 37 °C with 4 μM Fluo-
3 AM (Sigma Chemical, St. Louis, MO) in the presence of
0.5 % Me2SO and 0.1 % of the nonionic surfactant pluronic
acid F-127, the cells were then washed three times with
DMEM containing 10 % FBS. Fluo-3 AM fluorescence
excitation was done by Argon ion laser at 488 nm, with
fluorescence-emission collection at 510–530 nm with a
band-pass filter. The changes in [Ca2+]i levels were recorded
every 10 s. After reading each sample, a 4-Br-A23187
ionophore (5 μM) and an EGTA chelating compound
(10 mM) were used to determine maximal (Fmax) and
minimal (Fmin) fluorescence values, respectively. Intracel-
lular free-calcium concentrations were calculated from rela-
tive fluorescence values by using the equation [Ca2+]i0Kd
(F – Fmin)/(Fmax – F), assuming 450 nM Kd for fluo-3
calcium binding [40].
Gene expression analysis related to ER stress response
by real-time PCR
Polymerase chain reaction (PCR) was applied to real time
quantitative expression analysis of those genes related to
ER-stress response. cDNA strands were constructed with
total RNA extracted from RENCA cells, using a cDNA
Cycle Kit for RT-PCR kit (Invitrogen™, Life Technologies
Inc.), according to manufacturer's instructions. Specific pri-
mers were used in the formation of double-stranded cDNA.
The StepOne Plus Real-Time PCR System (Applied Bio-
systems, Foster City, CA, USA) was applied to cDNA
amplification. Specific double-tranded DNA was labeled
with SYBR Green I provided in the SYBR Green PCR
Master Mix (Invitrogen™, Life Technologies Inc.), to so
facilitate quantitative detection of PCR products in a reac-
tion volume of 25 μL. The PCR procedure was an initial
10 min at 95 °C, followed by 40 cycles of denaturation of
15 s at 95 °C, 30 s at 60 °C, and finally 30 s at 72 °C. The
GAPDH (Glyceraldehyde-3-phosphate dehydrogenase)
gene expression level was used to normalize differences in
RNA isolation and degradation. The results were analyzed
by relative quantification between groups: control, using
2-ΔΔCT [41].
Determination of GRP78 and GADD153 protein expression
by Western blot
RENCA cells were grown in an appropriate medium until
reaching 80 % confluence. Once stabilized, the culture
medium was replaced, whereupon the cells were stimulated
with 0.5 μM of Amblyomin-X for periods of 2, 6 or 24 h.
They were then lysed with a RIPA buffer (1 % deoxycho-
late, 150 mM of NaCl, 1 % SDS, 10 mM of NaF, 1 % Triton
X-100, 50 mM of Tris–HCl), together with the protease
inhibitors, aprotinin (2 mg/mL), fenilmetilsulfonilfluoreto
(PMSF) (1 mM), and orthovanadate phosphatase (1 mM).
The resultant products were then incubated on ice for
20 min. After protein quantitation by the bicinchoninico
acid (BCA) method, using BSA as standard protein curve,
30 μg from each sample underwent electrophoresis on 10 %
SDS gel, prior to transferring to a PVDF membrane
(Hydrophobic polyviniylidene difluoride, Healthcare, USA),
using as transfer buffer 0.25 M Tris, 0.19 M glycine and
20 % methanol, under a constant voltage of 100 V for 1 h at
4 °C. In order to block nonspecific sites, the membrane was
incubated three times, first with a solution of 5 % BSA in
TBS-Tween (20 mM of Tris–HCl pH 7.4, 0.15 M of NaCl
and 0.2 % Tween), then with the primary antibodies anti-
GRP78 1:1000 (Santa Cruz Biotechnology Inc, CA, USA)
and anti-GADD153 1:200 (Santa Cruz Biotechnology Inc,
CA, USA), using as internal control anti-GAPDH 1:5000
(Sigma Aldrich, MO, USA), and finally with an HRP-
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conjugated secondary antibody (Sigma-Aldrich, MO, USA).
Immunostaining was revealed with an ECL solution and
detected by LAS4000 ImageQuant equipment (EG,
Germany). An Amersham Rainbow Full-Range molecular
weight marker (GE Healthcare, USA), was used for
comparing the position of the bands on the gel in use. The
ImageJ analysis program (National Institute of Health,
USA) was used for quantification of the bands thus found.
Determination of NO and H2O2 production
In order to determine NO production, 1x105 RENCA cells
were seeded onto 96-well-plates for posterior treatment with
0.1 μM of Amblyomin-X during 48 h. NO production was
monitored in the extracellular medium by assessing nitrite
levels with a Griess reagent. Briefly, 50 μL of cell-free
supernatants were added to 100 μL of Griess reagent
(5 % H3PO4, 1 % sulfanilamide, 0.1 %N-1-naphtyl-
ethylendiamine). Absorbance was measured at 540 nm.
Various concentrations of sodium nitrite were used in
the construction of a standard curve. All biochemical
analyses were performed in triplicate.
The assessment of H2O2 levels by microassaying, using a
technique described and adapted by Pick and Mizel [42],
consisted of the following. 2x105cells/mL of adherent
RENCA cells was suspended in 1 mL of RPMI-1640.
100 μL of the so formed suspension were placed into flat-
bottomed 96-well culture plates. In order to induce cell
adhesion, the plates were incubated for 1 h at 37°C in a
humidified atmosphere (5 % CO2). The wells were then
washed with PBS to remove non-adherent cells. A phenol
red solution was then added, prior to H2O2 assaying. This
was followed by incubation at 37 °C in a humid atmosphere
for 1 h. The reaction was stopped by adding 1 N sodium
hydroxide (NaOH). The tests were done in quadrupli-
cate. Control samples, without PMA stimulation, were
simultaneously evaluated to assess the spontaneous pro-
duction of H2O2. Absorbance was determined by way of
an ELISA reader with a 620 nm filter, to thus obtain
optical density (OD). The results are presented in nmols
of H2O2.
Statistical analysis
For comparative analysis of the two groups, treated or
untreated with Amblyomin-X, statistical significance
was determined by one- or two-way variance analysis
(ANOVA) followed by Bofferoni correction, as well as the
Tukey-Kramer or Dunnett post-tests, using GraphPad Prism
5.0 software (GraphPad Software Inc., San Diego, CA). The
criteria for statistical significance, set at P<0.05, were
represented by an asterisk (*). Data are expressed as
mean±SEM.
Results
Morphological apoptosis characteristics were observed
in RENCA cells treated with Amblyomin-X
RENCA cells treated with Amblyomin-X presented mor-
phological differences when compared to those un-treated
(Fig. 1). In the control group, a novel cell structure was
formed, through the expansion of a central condensed part
into long, branched structures projecting from cytoplasmic
interconnections and expansions of the cytoplasm and the
cytoskeleton (Fig. 1). In contrast, the group treated with
Amblyomin-X presented striking morphological changes,
characteristic of cells undergoing apoptosis, with apoptotic
body formation, the reduction of microvilli, loss of adhesion
to the matrix, and formation of membrane blebs. There is no
organization of the extracellular matrices, but appreciable
morphological changes, such as the formation of round cells
and cell debris (Fig. 1). Interestingly, NIH3T3 cells in both
the control and treated groups showed the same pattern of
cell morphology, with the presence of fibroblastoid spindle
cells, adhered to the contact surface of the culture plate, and
the formation of three-dimensional fiber and fibril high-
density networks connecting the external surfaces of cells
with cytoplasmic projections to adjacent cells. Furthermore,
there were no morphological modifications, such as cell
rounding or debris, and the well-preserved extracellular
matrix was juxtaposed between firmly adhered cells and
those recently proliferated. Moreover, cell division was
clearly visible (Fig. 1).
Amblyomin-X affects the balance between pro-apoptotic
and anti-apoptotic proteins and mitochondrial integrity
Analysis of Bcl-2 family expression levels by flow cytom-
etry revealed that treatment with 0.1 μM of Amblyomin-X
induces imbalance between pro- and anti-apoptotic proteins
in RENCA, but not in NHI3T3 cells. After 24 h of
Amblyomin-X treatment, there was a significant change in
protein expression levels, with an approximate 6-fold reduc-
tion in anti-apoptotic Bcl-2 proteins, and a 3.5-fold increase
in Bax and Bad (Fig. 2a, b and c). However, no changes
were observed in p53 expression levels in either RENCA or
NIH3T3 cells (Fig. 3), an indication that this protein is not
involved in the regulation of either expression or cytoplas-
mic activation in the Bcl-2 family.
As these proteins play a role in the maintenance of
mitochondrial integrity, and since dysfunction has been
noted, it was decided to investigate whether changes in
Bcl-2 family expression levels were accompanied by
changes in mitochondrial potential. Thus, by using the same
concentration of Amblyomin-X and the same treatment
period, it was observed that Amblyomin-X was capable of
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significantly reducing the mitochondrial potential in both
adherent RENCA cells and those present in the supernatant,
with no changes in NHI3T3 cells (Fig. 2d). Contributing to
this result, there was an approximate 3-fold increase in the
release of cytochrome c into the cytosol in RENCA cells
treated with Amblyomin-X, when compared to control
group. This was not observed in NHI3T3 cells, where no
changes in cytochrome c release were observed (Fig. 2e).
The effect of Amblyomin-X on caspase 3 catalytic activity
Caspase 3 catalytic activity in RENCA and NHI3T3 cells
was evaluated after a 24-hour-treatment with 0.1 μM of
Amblyomin-X. The proportion of caspase 3 phosphoryla-
tion and activation by Amblyomin-X in RENCA cells
was about 7 times higher than in the control group
(Fig. 4). This could arise from the observed cytochrome
c release (Fig. 2e). On the other hand, no like difference
was observed in either treated or untreated NHI3T3
cells (Fig. 4).
Proteasome inhibition by Amblyomin-X
Previous studies have shown that Amblyomin-X is capable
of negatively modulating proteasome activity in SK-Mel-28
and Mia-Paca-2 tumor human strains, through preferentially
inhibiting the trypsin-like site and increasing the pool of
poly-ubiquitinated proteins [34]. This strongly implies that
this activity could be an Amblyomin-X target for triggering
cytotoxic effects. Results obtained with RENCA cells
showed that 4 and 16 h after treatment with 0.1 μM
Amblyomin-X, there was a significant decrease in
chymotrypsin-like proteasome activity (Fig. 5). After 16 h
of incubation, the reduction was 4-fold, when compared to
controls.
Amblyomin-X-induces ER stress in RENCA cells
On seeking to correlate the effects of Amblyomin-X on pro-
teasome functions and ER stress in RENCA cells, it was
decided to evaluate whether this molecule was capable of
causing ER stress. Hence, its capacity to interfer with [Ca2+]
and the expression of targets related to ER stress, was analyzed.
Throughmicrofluorimetry, the increase in [Ca2+]iwas instan-
taneous, although not transient, in Amblyomin-X treated
RENCA cells, suggesting an induced calcium homeostasis dis-
turbance. For instance, immediately after applying of 0.1 μMof
Amblyomin-X, there was a change in the pattern of fluores-
cence, without the peak response reaching a maximum (data
not shown). Thus, in order to assess [Ca2+]i mobilization after
longer periods of treatment, quantification by confocal micros-
copy was resorted to, whereby it was possible to visualize the
fluorescence of cells pre-incubated with Amblyomin-X and
treated with Fluo-3 AM (Fig. 6a). The analysis of [Ca2+]i
elevation during Amblyomin-X treatment, revealed that after
5 and 24 h, there was a significant increase—about three- and
five-fold, respectively—in the amount of free ions, when com-
pared to control. Nevertheless, on comparing 5-hour and
24-hour treatments, there was no significant difference indicat-
ing that Amblyomin-X had reached its maximum response.
The capacity of Amblyomin-X to affect gene expression
of targets related to ER stress pathways was tested through
real-time PCR. Interestingly, after treating RENCA cells
with 0.5 μM of Amblyomin-X for 2 h, a significant reduc-
tion of around 30 % in mRNA GRP78 levels occurred,
followed by a pronounced increase in expression after 6
and 24 h, of 30 and 80 %, respectively (Fig. 6b). A similar
pattern was observed for the GADD153 gene expression,
with a 12 % reduction in expression after 2 h of treatment,
and an increase of about 15 % and 100 % after 6 and 24 h,
respectively, without any significant difference (Fig. 6b).
Control Amblyomin-X
RENCA
NHI3T3
Fig. 1 Morphological
differences between RENCA
and NIH3T3 cells treated
with Amblyomin-X. Photomi-
crographs of cells treated with
0.1 μM of Amblyomin-X for
24 h, and untreated ones
(control), observed and ana-
lyzed by SEM. (RENCA Con-
trol) Details of extracellular
matrix organization. (RENCA
Amblyomin-X) Apoptotic
bodies and cell-membrane dis-
ruption. (NHI3T3 Control)
Spindle cells, extracellular ma-
trix organization and fibrillar
collagen arrangement.
(NHI3T3 Amblyomin-X)
Fibroblastoid cells adhered to
the surface and extracellular
matrix organization
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It was thus indicated that ER is involved in the mecha-
nism of Amblyomin-X action, although it was not clear
whether this was through GRP78 reduction or ER stress.
Thus, it was decided to assess the levels of GRP78 and
GADD153 protein expression under the same conditions
of real-time PCR. A correlation between gene and protein
expression became apparent. After 24 h of treatment with
Amblyomin-X, there was a 70 % increase in GRP78
protein levels, compared to untreated cells (Fig. 6c and d).
Moreover, although GADD153 protein levels decreased in
the interval between 2 to 6 h, this was followed by a
significant increase of about 235 % in treated cells after
24 h (Fig. 6c and e). Thapsigargin was used for 6 h, as
positive control at 0.5 μM.
Modulation of NO and H2O2 production by Amblyomin-X
The production of NO and H2O2 in RENCA cells was
analyzed along the same lines followed in the experiments
with Ca2+ and the expression of targets related to ER stress.
Fig. 2 Imbalance between pro-and anti-apoptotic Bcl-2 family pro-
teins, accompanied by mitochondrial function impairment, is caused
by Amblyomin-X. RENCA and NHI3T3 cells were treated with
0.1 μM of Amblyomin-X during 24 h. a Bcl-2 expression. b Bad
expression. c Bax expression. d Representative histograms of mito-
chondrial membrane potential. e Release of cytochrome c. Experiment-
monitoring was by flow cytometry. The data are presented as mean±
SEM. *P<0.05 vs. control
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After 48 h of 0.1 μM Amblyomin-X treatment, there was a
reduction of 40 % in NO production, when compared to
untreated cells (Fig. 7a), and after 24 h, a 44 % increase in
H2O2 levels (Fig. 7b), thereby indicating that changes
in oxidative conditions of RENCA cells treated with
Amblyomin-X induced ROS production.
Discussion
Cell death and survival are topics under constant discussion
in scientific literature, however, it has become increasingly
evident that these processes are regulated by a sophisticated
balance between pro- and anti-apoptotic proteins and highly
dynamic interactions that lead cells to a final destination
[43, 44]. Hence, the present study demonstrated that
Amblyomin-X promotes apoptotic morphological character-
istics into tumor cells, accompanied by imbalance between
the protein levels of Bcl-2 family members by decreasing
anti-apoptotic and increasing pro-apoptotic levels, without
p53 participation. Interestingly, there are several clinical and
preclinical anti-tumor drugs, for example, ABT-737, that
target members of the Bcl-2 family, and many studies argue
that the reduction of Bcl-2 and Bcl-XL would be sufficient
to induce cell apoptosis [13, 45, 46].
Mitochondria are also predominant target in the
search for novel anti-tumor therapies. Accordingly, in-
terest has recently been focused on a new class of
drugs, the mitocans, which act through tumor cell mi-
tochondria, without affecting normal ones [47, 48]. The
mechanism of their action is based on the ability to
disrupt cellular energy production systems by way of
mitochondria, thereby leading to an increase in reactive
oxygen species and the activation of cell death by
signaling mitochondria dependent pathways. Apart from
their efficacy, these drugs have become additionally
attractive through presenting few side effects on normal
cells in in vivo experiments [48]. These characteristics
were observed in tumor cells treated with Amblyomin-
X, by compromising the mitochondrial membrane po-
tential, the release of cytochrome c, and the increased
production of ROS, observed by an increase in H2O2
levels. These results suggest, thereby, that these
responses can lead to caspase 3 activation, ultimately
culminating in apoptosis.
Apparently, Amblyomin-X induces ER stress by neg-
atively modulating proteasome activity. This is charac-
terized by an increase in the concentration of free
intracellular Ca2+ ([Ca2+]i), and changes in GRP78 and
GADD153 protein levels, considered classical markers
of the process. Proteasome inhibition can also lead to
the accumulation of proteins bearing conformational-
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Fig. 4 Amblyomin-X induces caspase 3 activation. Detection of phos-
phorylated caspase-3 by flow cytometry in RENCA and NHI3T3 cells
treated with 0.1 μM of Amblyomin-X during 24 h. The data are
presented as mean±SEM. ***P<0.0005 vs. control
Fig. 5 Inhibition of proteasome activity by Amblyomin-X. RENCA
cells were treated with 0.1 μM Amblyomin-X for 4 and 16 h, as
indicated. ChT-L and T-L proteasomal activities were defined in the
cell extracts, as described in Material and Methods. Results shown are
expressed as percentages of control samples. ChT-L, chymotrypsin-
like and T-L, trypsin-like activities, respectively. The data are repre-
sented as mean±SEM. ***P<0.0005 vs. control
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Fig. 3 Amblyomin-X action is p53 independent. RENCA and
NHI3T3 cells were treated with 0.1 μM of Amblyomin-X during
24 h. Experiment-monitoring was performed by flow cytometry. The
data are presented as mean±SEM. *P<0.05 vs. control
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structure damage, a condition which can lead to ER
stress [29, 30, 49]. Cell response consists of the release
of ER Ca2+ stores, which is either taken up by mito-
chondria, or directed to other intracellular destinations,
thereby activating a signaling cytoprotective response,
denominated ‘unfolded protein response’ (UPR) [50].
One of the characteristic effects of UPR is translational
attenuation, a form of reducing new-protein synthesis,
and so avoiding the accumulation of proteins with con-
formational defects. This is accomplished by phosphor-
ylation of the eIF2α, an event that redirects transcript
alternative targets, such as chaperones (e.g., GRP78),
and proteasome subunits [32]. However, if UPR is sup-
pressed by sustained proteasome inhibition, stress can
lead to severe and prolonged ER-activating death path-
ways [25, 51]. In parallel, the induction of transcription
factors, such as pro-apoptotic growth arrest and DNA
gene product GADD153, may also occur. GADD153 is
a nuclear transcription factor that represses Bcl-2 pro-
motors, and is capable of sensitizing mitochondria to
the pro-apoptotic effects of BH3-only proteins. Its over-
expression can lead to cell-cycle arrest and apoptosis
[52]. GADD153 expression, mainly regulated at the
transcriptional level, is one of the most highly induced
during ER stress [52].
There appear to be several anti-tumors, such as cur-
cumin, salubrinal, bortezomib and sorafenib, whose in-
dividual action are similar of Amblyomin-X mechanism,
by inhibiting proteasome activity and causing ER stress
[23, 24, 29, 53]. Similarly, some of these drugs act
selectively on tumor cells. There is some discussion to
explain this phenomenon, i.e., cycling cells are possibly
Fig. 6 Amblyomin-X induces ER stress in RENCA cells. a Through
confocal microscopy—the graphical representation of Ca2 + quantita-
tive influx in unstimulated cells, and RENCA cells stimulated with
0.5 μM Amblyomin-X for 5 and 24 h. b By real-time PCR—levels of
gene expression of targets related to ER stress. Cells were treated with
0.5 μM of Amblyomin-X for 2, 6 and 24 h. c Western blot analysis of
samples with or without treatment (Ctrl) using anti-GRP78, anti-
GADD153 and anti-GAPDH, as endogenous controls. d and e
Densitometry analysis of protein bands revealed with anti-GRP78
and anti-GADD153 relative to control. Values are mean±SD of three
independent experiments. *P<0.05 compared to control (untreated cells)
Fig. 7 Changes in oxidative conditions of RENCA cells in the pres-
ence of Amblyomin-X. a NO levels in RENCA cells treated with
0.1 μM of Amblyomin-X for 48 h. b H2O2 levels in RENCA cells
treated with 150 nM of Amblyomin-X for 24 h. The values are the
mean±standard deviation of three independent experiments. *P<0.05
vs. control
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more sensitive to proteasome inhibition than resting
ones. This is probably due to so many crucial cell-
cycle checkpoints being regulated by proteasome activ-
ity, or by displaying a higher baseline rate of translation
compared to other cells. This could make them more
vulnerable to protein buildup, and the subsequent ER
stress caused by proteasome activity. Even so, as yet,
nothing is conclusive [23, 24, 29, 53].
Apparently, there is an interrelationship between mi-
tochondrial dysfunction, ROS production, and ER stress.
Mitochondrial dysfunction and ER stress are capable of
producing ROSs, or even inducing the establishment of
such cell conditions [54]. ER stress and ROS production
also play a role in the modulation of Bcl-2 family
proteins, as well as inducing mitochondrial damage [9,
55]. For example, as shown here, the Amblyomin-X
induced increase in H2O2 and decrease in NO levels
are both related to Bcl-2 protein instability and deacti-
vation. Concomitantly, the Bcl-2 pro-apoptotic protein
family can initiate apoptosis via ER, thereby directly
affecting Ca2 + stocks and caspase-12 activation
[54–57]. It was found that proteasome inhibition (4
and 16 h of treatment) and responses related to ER
stress, such as changes in gene expression of ER stress
marker proteins and (Ca2 +)i levels, were observed ear-
lier (between 5 and 6 h of treatment), than responses related
to mitochondrial damage, such as, cytochrome c release and
ROS production (24 h of treatment). This presupposes
Amblyomin-X begins pro-apoptotic signaling by way of ER
stress. Notwithstanding, there is no way of ruling out the
possibility of this molecule activating these pathways separate-
ly, and that their individual cellular response converge in
Fig. 8 Possible mechanisms involved in Amblyomin-X pro-apoptotic
action in RENCA cells. Amblyomin-X causes: (i) protein imbalance
between pro- and anti-apoptotic Bcl-2 family proteins; (ii) mitochon-
drial dysfunction, marked by changes in its membrane potential and
release cytochrome c; (iii) activation of caspases, (iv) proteassomal
inhibition; (v) ER stress, characterized by induced expression in the
respective protein markers (GRP78 and GADD153) and changes in
(Ca2+) levels. Hypothetically, Amblyomin-X could act separately in
these cell pathways responses, or even synergistically between them,
converging in apoptosis. Nevertheless, more conclusive studies are
required to confirm this hypothesis (adapted from [9, 33, 54–57])
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apoptosis, or proceed until reaching the point of synergy
between the pathways (Fig. 8). Novel experimental
approaches are required to confirm this hypothesis.
Conclusions
Amblyomin-X is an FXa inhibitor of the Kunitz-type that has
anti-tumor activity. Even so, the cell-events triggered by this
molecule have not, as yet, been finally defined. Nevertheless,
its apoptotic effect on RENCA cells is hereby confirmed. This
effect comprises: (a) induces protein imbalance between pro-
and anti-apoptotic Bcl-2 family proteins; (b) mitochondrial
dysfunction, marked by changes in its membrane potential
and release of cytochrome c; (c) caspase 3 activation, (d)
proteasomal inhibition; (e) ER stress, characterized by the
induction of specific protein marker expression (GRP78 and
GADD153) and changes in (Ca2+)i levels (Fig. 8). In view of
its selective action on tumor cells, since no significant change
was observed in NIH3T3 cells treated with Amblyomin-X,
and of the current efforts to develop effective cancer-combat
therapies, these results are relevant to understanding the
Amblyomin-X mechanism of action, and to its appointment
as an effective therapeutic agent candidate.
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